J.D. Tuccille on 3D Printing Drugs
Orphan drug regulations are intended ease the regulatory process and lower barriers for medicines that address rare medical conditions. Otherwise, the costs of research, winning regulatory approval, and production could well exceed anything a pharmaceutical company could hope to recoup in an era when developing a new drug can cost a billion—or billions—of dollars. Bringing down regulatory costs is a necessary but elusive goal that may well require intervention by the federal policy fairies. But, as Reason 24/7 Managing Editor J.D Tuccille points out, both research and production look poised for a revolution, as 3D printing applies its high-tech charms to the business of creating chemical compounds, and turns the production of medicine into a DIY project. Not incidentally, the revolution also promises to kneecap whatever is left of efforts to control recreational drugs.
Hide Comments (0)
Editor's Note: As of February 29, 2024, commenting privileges on reason.com posts are limited to Reason Plus subscribers. Past commenters are grandfathered in for a temporary period. Subscribe here to preserve your ability to comment. Your Reason Plus subscription also gives you an ad-free version of reason.com, along with full access to the digital edition and archives of Reason magazine. We request that comments be civil and on-topic. We do not moderate or assume any responsibility for comments, which are owned by the readers who post them. Comments do not represent the views of reason.com or Reason Foundation. We reserve the right to delete any comment and ban commenters for any reason at any time. Comments may only be edited within 5 minutes of posting. Report abuses.
Please
to post commentsMute this user?
Ban this user?
Un-ban this user?
Nuke this user?
Un-nuke this user?
Flag this comment?
Un-flag this comment?